NewLink Gets a Hold Rating from Cantor Fitzgerald

By Carrie Williams

Cantor Fitzgerald analyst Mara Goldstein maintained a Hold rating on NewLink (NASDAQ: NLNK) yesterday and set a price target of $7. The company’s shares closed on Friday at $4.47, close to its 52-week low of $3.76.

Goldstein commented:

“Data from a Phase I study of indoximod in diffuse intrinsic pontine glioma (DIPG) presented at AACR were positive, in our view, but given the recent failure of Incyte’s (INCY, NC) epacadostat, we do not believe that is likely to sway investors at this point.”

According to TipRanks.com, Goldstein is a 1-star analyst with an average return of -1.2% and a 37.7% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Corvus Pharmaceuticals Inc, and Karyopharm Therapeutics.

Currently, the analyst consensus on NewLink is Hold and the average price target is $9.50, representing an 112.5% upside.

In a report issued on April 6, Merrill Lynch also downgraded the stock to Hold.

The company has a one-year high of $20.47 and a one-year low of $3.76. Currently, NewLink has an average volume of 1.11M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians.